PEPTIDE THERAPEUTICS: FDA Regulatory Update & Proposed Timeline | April 2026
Yoon Hang Kim MD
Yoon Hang Kim, MD, MPH | www.directintegrativecare.com
KEY DISTINCTION: Removal from Category 2 does NOT equal Category 1 approval. Peptides removed from Category 2 currently occupy regulatory limbo as unapproved new drugs. Full legal compounding access requires PCAC review, a favorable recommendation, and final FDA rulemaking. Until that formal publication occurs, prescribing or dispensing these compounds carries federal enforcement risk. (Source: Holt Law, April 2026; FDA.gov Docket FDA-2025-N-6895) |
Regulatory Timeline
Sept 2023 | FDA adds 19 peptides to Category 2 (significant safety concerns), halting all 503A compounding overnight. Affected: BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu (injectable), Thymosin Alpha-1, Semax, Selank, Epitalon, KPV, MOTS-C, Melanotan II, LL-37, PEG-MGF, GHRP-2, GHRP-6, Ibutamoren, Kisspeptin-10. |
Sept 2024 | FDA removes 5 peptides from Category 2 (nominations withdrawn): AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank — effective Sept 27, 2024. Status: regulatory limbo — removed from Category 2 but not yet on approved compounding list. PCAC review scheduled. |
Oct–Dec 2024 | PCAC meetings held. Oct 29: Ipamorelin, Ibutamoren, Kisspeptin reviewed — FDA recommended NONE be included on 503A Bulks List. Dec 4: AOD-9604, CJC-1295, Thymosin Alpha-1 reviewed. Outcome: PCAC accepted FDA staff recommendations against inclusion for most peptides reviewed in this cycle. Formal rulemakings pending. |
Feb 27, 2026 | HHS Secretary RFK Jr. announces on Joe Rogan Experience (Episode #2461) that ~14 of 19 Category 2 peptides will return to legal compounding status. Rationale: Category 2 restrictions "created the gray market they were designed to prevent." Formal FDA action to follow. |
Apr 15, 2026 | HHS directs FDA to remove 12 peptides from Category 2. Effective April 22, 2026 (7 calendar days from publication). Includes: BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, Emideltide (DSIP), GHK-Cu (injectable), Melanotan II, Cathelicidin LL-37, Dihexa Acetate, and others. Each will proceed to PCAC review. |
Apr 16, 2026 | FDA publishes Federal Register notice (Docket FDA-2025-N-6895) formally scheduling PCAC meetings. Public comments accepted through July 22, 2026; comments by July 9 presented to committee. |
Jul 23–24, 2026 | PCAC Advisory Meeting — BATCH 1 (7 peptides): July 23: BPC-157 (ulcerative colitis indication), KPV (wound healing), MOTS-C, TB-500. | July 24: Emideltide (DSIP), Epitalon, Semax. |
Late 2026 | FDA final determination for Batch 1 peptides expected. If PCAC recommends inclusion, FDA must publish final rule before compounding pharmacies can legally produce. Earliest estimated legal compounding access for BPC-157, TB-500, Semax, Epitalon: Late 2026–Early 2027. |
By Feb 2027 | PCAC Advisory Meeting — BATCH 2 (5+ peptides): GHK-Cu (injectable), Melanotan II, CJC-1295 (status disputed), Cathelicidin LL-37, and others. Final rulemakings for Batch 2 compounds: 2027 at earliest. |
Projected Peptide Status (Based on April 2026 Announcements)
Expected to return to Category 1 (~14 peptides) | Expected to remain restricted (~5 peptides) |
|---|---|
✓ BPC-157 PCAC Jul 23, 2026 | ✗ Melanotan II cardiovascular / melanoma risk |
✓ TB-500 PCAC Jul 23, 2026 | ✗ GHRP-2 / GHRP-6 cortisol & prolactin effects |
✓ Thymosin Alpha-1 PCAC Dec 2024 reviewed | ✗ CJC-1295 cardiac AE signal; status disputed |
✓ Ipamorelin PCAC Oct 2024 reviewed | ✗ LL-37 (Cathelicidin) insufficient human safety data |
✓ AOD-9604 PCAC Dec 2024 reviewed | ✗ PEG-MGF minimal clinical evidence |
✓ GHK-Cu (injectable) PCAC by Feb 2027 | |
✓ Selank Removed Sept 2024 | |
✓ Semax PCAC Jul 24, 2026 | |
✓ KPV PCAC Jul 23, 2026 | |
✓ MOTS-C PCAC Jul 23, 2026 | |
✓ Epitalon PCAC Jul 24, 2026 | |
✓ Emideltide (DSIP) PCAC Jul 24, 2026 |
Clinical Guidance for Prescribers
|
Yoon Hang "John" Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine 20+ years experience | Fellowship-trained at University of Arizona under Dr. Andrew Weil | Author of 3 books & 20+ articles www.yoonhangkim.com | www.directintegrativecare.com | Virtual: IA | IL | MO | FL | GA | TX |
